查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403489

到 2030 年阿斯匹靈藥物的市場預測：按產品、劑型、配銷通路和地區進行的全球分析

Aspirin Drug Market Forecasts to 2030 - Global Analysis By Product (Ecotrin, Bufferin, Generic Aspirin and Other Products), Dosage Form, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球阿斯匹靈藥品市場規模為 25 億美元，預計到 2030 年將達到 36 億美元，預測期內複合年成長率為 5.4%。

阿斯匹靈藥品市場包括含有乙醯水楊酸的藥品，俗稱阿斯匹靈，是一種廣泛使用的藥物，具有鎮痛、發炎和解熱作用。阿斯匹靈屬於一類非類固醇消炎劑(NSAID)，用於緩解疼痛、抑制發炎和發燒控制。此外，阿斯匹靈已被證明具有抗凝血特性，可用於預防心臟病和中風等心血管事件。

根據美國國家公共衛生機構疾病管制與預防中心的報告，美國四分之一的成年人被醫生診斷出患有關節炎，即約有 5,850 萬人被診斷出患有關節炎。

對心血管健康的益處

阿斯匹靈具有抗血小板特性，因其降低心臟病和中風等心血管事件風險的能力而受到廣泛認可。這種藥物的作用是抑制血栓的形成，這是預防血管阻塞的關鍵因素，血管阻塞可能導致嚴重的心血管問題。醫生經常開立阿斯匹靈作為有心血管疾病史或高危險群的預防措施。此外，阿斯匹靈對於治療心肌梗塞等急性疾病也有效，進一步凸顯了阿斯匹靈在心血管治療中的重要性。隨著人們對預防性醫療保健的重要性以及阿斯匹靈在降低心血管風險方面的作用的認知不斷增強，阿斯匹靈的需求繼續受到其既定的挽救生命的心血管健康益處的推動。

提高對潛在副作用的認知

隨著有關阿斯匹靈副作用的資訊越來越廣泛，醫療保健專業人員和消費者在使用阿斯匹靈時變得更加謹慎。潰瘍和出血等胃腸道併發症的風險是眾所周知的問題。這種認知的提高促使醫療保健專業人員更加謹慎地開藥，並考慮具有更有利副作用的替代藥物。然而，患者越來越意識到潛在的風險，這影響了他們使用阿斯匹靈的意願，尤其是長期使用。

世界高齡化

全球老年人數量不斷增加，與老齡化相關的健康狀況，特別是心血管疾病的盛行率很高。阿斯匹靈因其對心血管系統的影響而聞名，通常為老年人開處方，以預防心臟病和中風。老年人發生血栓事件的風險往往增加，這使得阿斯匹靈成為醫療保健的重要組成部分。此外，隨著年齡的成長，他們變得更容易受到疼痛和發炎相關病症的影響，進一步增加了對阿斯匹靈作為鎮痛和發炎藥物的需求。

出血風險

阿斯匹靈的抗凝血作用對於預防心血管事件很重要，但也會增加出血併發症的風險。這種擔憂對於接受外科手術的患者或有出血性疾病病史的患者尤其重要。醫療保健專業人員在開處方時必須仔細考慮阿斯匹靈的益處和潛在副作用之間的微妙平衡。然而，對出血事件的恐懼可能會阻止服用阿斯匹靈，特別是在必須仔細評估風險效益比的某些患者群體中。

COVID-19 的影響：

人們越來越認知到 COVID-19 患者可能出現心血管併發症，導致作為預防措施的阿斯匹靈處方量激增。由於阿斯匹靈具有抗血小板作用，因此人們通常認為它在降低與重症 COVID-19 病例相關的血栓事件風險方面具有潛在作用。然而，大流行期間醫療保健服務的中斷、患者優先事項的轉變以及處方模式的轉變正在影響全球市場。

Ecotrin 預計將在預測期內成為最大的細分市場

Ecotrin 部門由於專注於腸溶阿斯匹靈製劑，在預測期內佔據阿斯匹靈製劑的最大全球市場佔有率。 Ecotrin 是一個以其腸溶阿斯匹靈配方而聞名的品牌，該配方解決了通常與阿斯匹靈使用相關的胃腸道副作用問題。此外，腸溶衣可以讓阿斯匹靈通過胃而不會引起刺激，從而在腸道中釋放藥物並被吸收。這項創新技術降低了胃潰瘍和出血的風險，並提高了需要長期阿斯匹靈治療的患者的藥物耐受性。

咀嚼片預計在預測期內複合年成長率最高。

隨著市場對患者便利性和用藥醫囑遵從性的要求不斷提高，咀嚼片提供了比傳統錠劑更偏好、更容易使用的替代品。這項創新對吞嚥錠劑有困難的人很有吸引力，例如老人和兒童。咀嚼片細分市場利用了對更方便、更愉快的給藥體驗的需求，有助於提高患者的依從性。此外，阿斯匹靈咀嚼片的宜人味道使其成為尋求非處方止痛藥的人的首選。

佔比最高的地區

由於人們對心血管健康的認知不斷提高、慢性病的迅速增加以及高齡化的加劇，預計亞太地區將在預測期內佔據最大的市場佔有率。隨著該地區國家經歷經濟發展和都市化，生活方式也在不斷變化，導致久坐習慣增加和飲食習慣改變，引發健康問題。作為一個額外的好處，心血管疾病的盛行率不斷增加以及人們對阿斯匹靈預防功效的了解不斷增加，正在推動對該藥物的需求增加。

複合年成長率最高的地區：

歐洲高齡化和心血管疾病的高盛行率增加了對阿斯匹靈預防心臟病和中風的需求。該地區強調實證醫學，強大的法律規範支持阿斯匹靈在各種臨床環境中的持續處方和使用。此外，由於心血管健康仍然是歐洲醫療保健系統的主要關注點，阿斯匹靈作為一種具有成本效益且廣泛使用的藥物的作用預計將增加該地區對心血管疾病管理和預防的貢獻。承諾，我們正在為該地區阿斯匹靈市場的繁榮做出重大貢獻。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球阿斯匹靈藥品市場：依產品

  • 生態素
  • 緩衝素
  • 非專利阿斯匹林
  • 其他產品

第6章全球阿斯匹靈藥品市場：依劑型分類

  • 腸溶片
  • 咀嚼片
  • 可溶錠劑或發泡
  • 其他劑型

第7章全球阿斯匹靈藥品市場：依配銷通路

  • 藥局/藥局
  • 網路零售商
  • 雜貨店和超級市場
  • 批發商
  • 其他配銷通路

第8章全球阿斯匹靈藥品市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Cadila Healthcare Limited
  • Alembic Pharmaceuticals Limited
  • GlaxoSmithKline Consumer Healthcare Ltd
  • Takeda Pharmaceutical Company Limited
  • Torrent Pharmaceuticals Ltd
  • Abbott Laboratories
  • Aspen Pharmacare Holdings Limited
  • Dr. Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Novartis International AG
  • Pfizer Inc
  • Bayer AG
  • Roche Holding AG
Product Code: SMRC24714

According to Stratistics MRC, the Global Aspirin Drug Market is accounted for $2.5 billion in 2023 and is expected to reach $3.6 billion by 2030 growing at a CAGR of 5.4% during the forecast period. The aspirin drug market encompasses pharmaceutical products containing acetylsalicylic acid, commonly known as aspirin, which is a widely used medication with analgesic, anti-inflammatory, and antipyretic properties. Aspirin belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and is utilized for pain relief, reduction of inflammation, and fever management. Additionally, aspirin is recognized for its anticoagulant effects, contributing to its application in preventing cardiovascular events such as heart attacks and strokes.

According to a report shared by the Centers for Disease Control and Prevention, a US-based national public health agency, 1 in 4 adults in the US were suffering from doctor-diagnosed arthritis, which is almost 58.5 million people.

Market Dynamics:

Driver:

Cardiovascular health benefits

Aspirin, with its antiplatelet properties, is widely recognized for its ability to reduce the risk of cardiovascular events, including heart attacks and strokes. The drug works by inhibiting the formation of blood clots, a crucial factor in preventing blockages in blood vessels that can lead to severe cardiovascular issues. Physicians often prescribe aspirin as a preventive measure for individuals with a history of cardiovascular diseases or those at higher risk. Additionally, the drug's efficacy in managing acute conditions, such as myocardial infarction, further underscores its importance in cardiovascular care. As awareness grows regarding the significance of preventive healthcare and the role of aspirin in reducing cardiovascular risks, the demand for aspirin continues to be driven by its well-established and life-saving cardiovascular health benefits.

Restraint:

Growing awareness of potential side effects

As information about the adverse effects associated with aspirin becomes more widely disseminated, both healthcare professionals and consumers exercise increased caution in its usage. The risk of gastrointestinal complications, such as ulcers and bleeding, is a well-documented concern. This heightened awareness has led to more prudent prescribing practices by healthcare providers, who may consider alternative medications with a more favorable side effect profile. However, patients are becoming more informed about the potential risks, impacting their willingness to use aspirin, particularly for long-term applications.

Opportunity:

Global aging population

With an increasing number of elderly individuals worldwide, there is a higher prevalence of age-related health conditions, particularly cardiovascular diseases. Aspirin, known for its cardiovascular benefits, is commonly prescribed to the aging demographic as a preventive measure against heart attacks and strokes. The elderly population often experiences a higher risk of thrombotic events, making aspirin a key component in their healthcare regimen. Additionally, as people age, they may be more susceptible to conditions associated with pain and inflammation, further contributing to the demand for aspirin as an analgesic and anti-inflammatory medication.

Threat:

Risk of bleeding

While aspirin's anticoagulant properties are crucial for preventing cardiovascular events, they concurrently elevate the risk of bleeding complications. This concern is particularly relevant for individuals undergoing surgical procedures or those with pre-existing bleeding disorders. The delicate balance between aspirin's benefits and potential adverse effects requires careful consideration by healthcare professionals when prescribing the drug. However, the fear of bleeding events may lead to hesitancy in prescribing aspirin, especially in certain patient populations where the risk-benefit ratio must be meticulously assessed.

COVID-19 Impact:

The increased awareness of potential cardiovascular complications in COVID-19 patients has led to a surge in aspirin prescriptions as a preventive measure. As aspirin exhibits antiplatelet properties, it is often considered for its potential role in mitigating the risk of thrombotic events associated with severe COVID-19 cases. However, disruptions in healthcare services, shifts in patient priorities, and altered prescribing patterns during the pandemic have influenced the market globally.

The ecotrin segment is expected to be the largest during the forecast period

Ecotrin segment commanded the largest market share of aspirin drug globally over the projected period due to its focus on enteric-coated aspirin formulations. Ecotrin, a brand recognized for its enteric-coated aspirin products, addresses the issue of gastrointestinal side effects commonly associated with aspirin use. Furthermore, the enteric coating enables the aspirin to pass through the stomach without causing irritation, releasing the medication in the intestines where absorption occurs. This innovation reduces the risk of stomach ulcers and bleeding, enhancing the drug's tolerability for patients requiring long-term aspirin therapy.

The chewable tablets segment is expected to have the highest CAGR during the forecast period

With a growing market trend toward patient convenience and adherence, chewable aspirin tablets offer a more palatable and user-friendly alternative to traditional pill forms. This innovation appeals to individuals who may have difficulty swallowing pills, including the elderly and children. The Chewable Tablets segment is capitalizing on the demand for a more accessible and enjoyable medication experience, contributing to increased patient compliance. Furthermore, the pleasant taste of chewable aspirin tablets makes them a favorable choice for individuals seeking over-the-counter pain relief options.

Region with largest share:

Due to the rising awareness of cardiovascular health, a surge in chronic diseases, and an expanding aging population, Asia Pacific region is expected to hold largest market share over the forecast period. As countries in the region undergo economic development and urbanization, lifestyles are evolving, leading to an increase in sedentary habits and dietary changes that contribute to health concerns. Additionally, the growing prevalence of cardiovascular diseases in tandem with an increasing understanding of aspirin's preventive benefits is fostering a higher demand for this medication.

Region with highest CAGR:

Europe is expected to hold profitable growth owing to the region's aging population, coupled with a high prevalence of cardiovascular diseases, has propelled the demand for aspirin as a preventive measure against heart attacks and strokes. The region's emphasis on evidence-based medicine and a strong regulatory framework supports the continued prescription and use of aspirin in various clinical contexts. Additionally, as cardiovascular health remains a primary focus in European healthcare systems, aspirin's role as a cost-effective and widely available medication aligns with the region's commitment to managing and preventing cardiovascular diseases, thereby contributing significantly to the flourishing aspirin drug market in the region.

Key players in the market:

Some of the key players in Aspirin Drug market include Cadila Healthcare Limited, Alembic Pharmaceuticals Limited, GlaxoSmithKline Consumer Healthcare Ltd, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd, Abbott Laboratories, Aspen Pharmacare Holdings Limited, Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Novartis International AG, Pfizer Inc, Bayer AG and Roche Holding AG.

Key Developments:

In December 2023, Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical Co Ltd, has entered into a licensing agreement to co-develop and commercialise Leuprolide Acetate for Depot Suspension in six dosage strengths for the United States (US) market, the company in a regulatory filing with the BSE. The terms of the agreement will result in Zydus assuming full responsibility for the clinical development and commercialisation in the US market. Daewoong, on the other hand, will be responsible for the pre-clinical studies, production, and supply of the product.

In March 2023, Ahmedabad-based Cadila Pharmaceuticals has signed a Memorandum of Understanding (MoU) with the government of Gujarat to invest Rs 1,000 crore in different existing projects. The MoU was signed in Gandhinagar between Industries Commissioner Rahul Gupta on behalf of the government of Gujarat and Cadila Pharmaceuticals COO, Mitul Dave, under the Government of Gujarat's "Atma Nirbhar Gujarat Schemes for Assistance to Industries".

Products Covered:

  • Ecotrin
  • Bufferin
  • Generic Aspirin
  • Other Products

Dosage Forms Covered:

  • Enteric-Coated Tablets
  • Chewable Tablets
  • Dissolvable or Effervescent Tablets
  • Other Dosage Forms

Distribution Channels Covered:

  • Pharmacies and Drugstores
  • Online Retailers
  • Grocery Stores and Supermarkets
  • Wholesale Distributors
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Aspirin Drug Market, By Product

  • 5.1 Introduction
  • 5.2 Ecotrin
  • 5.3 Bufferin
  • 5.4 Generic Aspirin
  • 5.5 Other Products

6 Global Aspirin Drug Market, By Dosage Form

  • 6.1 Introduction
  • 6.2 Enteric-Coated Tablets
  • 6.3 Chewable Tablets
  • 6.4 Dissolvable or Effervescent Tablets
  • 6.5 Other Dosage Forms

7 Global Aspirin Drug Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Pharmacies and Drugstores
  • 7.3 Online Retailers
  • 7.4 Grocery Stores and Supermarkets
  • 7.5 Wholesale Distributors
  • 7.6 Other Distribution Channels

8 Global Aspirin Drug Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Cadila Healthcare Limited
  • 10.2 Alembic Pharmaceuticals Limited
  • 10.3 GlaxoSmithKline Consumer Healthcare Ltd
  • 10.4 Takeda Pharmaceutical Company Limited
  • 10.5 Torrent Pharmaceuticals Ltd
  • 10.6 Abbott Laboratories
  • 10.7 Aspen Pharmacare Holdings Limited
  • 10.8 Dr. Reddy's Laboratories Ltd
  • 10.9 Sun Pharmaceutical Industries Ltd
  • 10.10 Teva Pharmaceutical Industries Ltd
  • 10.11 Novartis International AG
  • 10.12 Pfizer Inc
  • 10.13 Bayer AG
  • 10.14 Roche Holding AG

List of Tables

  • Table 1 Global Aspirin Drug Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 4 Global Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 5 Global Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 6 Global Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 8 Global Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 9 Global Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 10 Global Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 11 Global Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 12 Global Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 14 Global Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 15 Global Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 16 Global Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 17 Global Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 18 North America Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 19 North America Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 20 North America Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 21 North America Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 22 North America Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 23 North America Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 24 North America Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 25 North America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 26 North America Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 27 North America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 28 North America Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 29 North America Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 North America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 31 North America Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 32 North America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 33 North America Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 34 North America Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 35 Europe Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 36 Europe Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 37 Europe Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 38 Europe Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 39 Europe Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 40 Europe Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 41 Europe Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 42 Europe Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 43 Europe Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 44 Europe Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 45 Europe Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 46 Europe Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 47 Europe Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 48 Europe Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 49 Europe Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 50 Europe Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 51 Europe Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 52 Asia Pacific Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 53 Asia Pacific Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 54 Asia Pacific Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 55 Asia Pacific Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 56 Asia Pacific Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 57 Asia Pacific Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 58 Asia Pacific Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 59 Asia Pacific Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 60 Asia Pacific Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 61 Asia Pacific Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 62 Asia Pacific Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 63 Asia Pacific Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 64 Asia Pacific Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 65 Asia Pacific Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 66 Asia Pacific Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 67 Asia Pacific Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 68 Asia Pacific Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 69 South America Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 70 South America Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 71 South America Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 72 South America Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 73 South America Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 74 South America Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 75 South America Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 76 South America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 77 South America Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 78 South America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 79 South America Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 80 South America Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 81 South America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 82 South America Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 83 South America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 84 South America Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 85 South America Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 86 Middle East & Africa Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 87 Middle East & Africa Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 88 Middle East & Africa Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 89 Middle East & Africa Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 90 Middle East & Africa Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 91 Middle East & Africa Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 92 Middle East & Africa Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 93 Middle East & Africa Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 94 Middle East & Africa Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 95 Middle East & Africa Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 96 Middle East & Africa Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 97 Middle East & Africa Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 98 Middle East & Africa Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 99 Middle East & Africa Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 100 Middle East & Africa Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 101 Middle East & Africa Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 102 Middle East & Africa Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)